GlassScriptPhysician profile
Aaron K Clark
NPI 1235113382
$2,496.30
in general payments reported to CMS, 2019-2025
33 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.84 · 2020: $25.91 · 2021: $124 · 2022: $609 · 2023: $471 · 2024: $637 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.02 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $280.67 | 2022-2025 | Ubrelvy |
| Pfizer INC. | $164.26 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $155.37 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $148.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $141.85 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $116.98 | 2022-2025 | Repatha, Repatha, Otezla |
| Carlsmed, INC. | $113.81 | 2022 | |
| Dexcom, INC. | $107.95 | 2022-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $102.44 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $74.97 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.29 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $69.74 | 2022 | |
| Lundbeck LLC | $69.04 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.57 | 2023-2024 | Jardiance, Tradjenta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.12 | 2023-2025 | Xifaxan, Relistor |
| Glaxosmithkline, LLC. | $57.72 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $51.64 | 2022-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $38.18 | 2022 | |
| Exact Sciences Corporation | $34.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kerecis Limited | $34.11 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Seqirus USA INC | $31.96 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Amarin Pharma, INC. | $31.90 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $27.09 | 2025 | Keveyis |
| Philips North America LLC | $25.13 | 2025 | Mcot |
| Atricure, INC. | $22.11 | 2025 | Atriclip Laa Exclusion System, Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System |
| Actelion Pharmaceuticals US, INC. | $20.85 | 2023 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $17.59 | 2022 | |
| Pulmonx Corporation | $14.54 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Sanofi-Aventis U.S. LLC | $13.83 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.24 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $11.82 | 2020 | |
| Almatica Pharma LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.